Anti-NMDAR encephalitis
Top Cited Papers
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To describe the detailed clinical characteristics, immunotherapy, and long-term outcomes of patients with anti-NMDA receptor (NMDAR) encephalitis in China. Methods A single-center, prospective study. Patients who met the diagnostic criteria were enrolled from 2011 to 2017 and followed up. The clinical features, treatment, and long-term outcomes were collected prospectively. Factors affecting the long-term prognosis were analyzed. Results The study included 220 patients. The most common clinical presentations were psychosis (82.7%) and seizures (80.9%). Of the patients, 19.5% had an underlying neoplasm; of which ovarian teratoma was 100% of tumors in females and only one male had lung cancer. Most patients (99.5%) received first-line therapy (glucocorticoids, IV immunoglobulin, or plasmapheresis alone or combined), and only 7.3% received second-line immunotherapy (rituximab, cyclophosphamide alone, or combined). Long-term immunotherapy (mycophenolate mofetil or azathioprine >1 year) was administered to 53.2% of patients. During the first 12 months, 207 (94.1%) patients experienced improvement, and 5 (2.3%) died, whereas 38 (17.3%) experienced relapses. At 12-month follow-up, 92.7% had favorable clinical outcomes (modified Rankin Scale score ≤2). Conclusions Patients in China present with psychosis and seizure frequently but have a low percentage of underlying neoplasms. Re-enforced first-line immunotherapy is effective in managing anti-NMDAR encephalitis in the acute phase. Although relapse is relatively common, with combined first-line and long-term immunotherapy, most patients reached favorable outcomes.Keywords
This publication has 21 references indexed in Scilit:
- Clinical Characteristics and Prognosis of Severe Anti-N-methyl-d-aspartate Receptor Encephalitis PatientsNeurocritical Care, 2018
- Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor EncephalitisChinese Medical Journal, 2018
- Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitisMultiple Sclerosis and Related Disorders, 2018
- Resection of melanocytic nevi as a potential treatment of anti-NMDAR encephalitis patients without tumor: report of three casesNeurological Sciences, 2017
- Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide surveyZeitschrift für Neurologie, 2017
- Anti-LGI1 encephalitisNeurology, 2016
- Anti‐NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest ChinaEuropean Journal of Neurology, 2015
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Analysis of relapses in anti-NMDAR encephalitisNeurology, 2011
- Anti-NMDA receptor encephalitis in JapanNeurology, 2008